39 research outputs found
Morfologičeskie harakteristiki pervoklassnyh gandbolistok
Utvrđena je najvažnija morfološka karakteristika vrhunskih rukometašica (jugoslavenskih reprezentativki) izražena longitudinalna dimenzionalnost skeleta.The study involved a sample of 66 Yugoslav female handballers that were representatives of the I and II leagues and the state team. The sample was used to determine the latent dimensions from the group of 12 anthropometric variables.
The results of the study show that the longitudinal dimensionality of the skeleton is significantly expressed in top handballers (Yugoslav representation) as opposed to the two other groups. The morphological characteristics such as the subcutaneous fat tissue and the volume and mass of the body are not statistically significant in any of the groups
Conditional IL-2 Gene Deletion: Consequences for T Cell Proliferation
To explore the role of interleukin-2 (IL-2) in T cell proliferation, and to circumvent the IL-2 deficiency autoimmune syndrome of conventional il2 gene deletion, mice were created to allow conditional il2 gene deletion when treated with the estrogen analog, tamoxifen (TAM) as adults. Splenocytes from four different mouse strains, C57Bl/6 wild type (WT), conventional IL-2(−/−), TAM-treated Cre recombinase-negative (Cre−)/IL2fl/fl, and Cre recombinase-positive (Cre+)/IL2fl/fl, were activated with anti-CD3 and anti-CD28, and monitored for CD4+ and CD8+ T cell lymphocyte blastogenesis, aerobic glycolysis, BrdU incorporation into newly synthesized DNA, and CFSE dye dilution to monitor cell division. IL-2 production was monitored by quantitative ELISA and multiple additional cytokines were monitored by quantitative protein-bead arrays. Splenocytes from conventional IL-2(−/−) and TAM-treated Cre+ mice resulted in undetectable IL-2 production by ELISA, so that both strains were IL-2-deficient. As monitored by flow cytometry, activated CD4+ and CD8+ T cells from WT, Cre+, and Cre− mice all underwent blastogenesis, whereas far fewer cells from conventional IL-2(−/−) mice did so. By comparison, only cells from IL-2 sufficient WT and Cre− mice switched to aerobic glycolysis as evidenced by a drop in media pH. Blastogenesis was mirrored by BrdU incorporation and CFSE dye dilution by CD4+ and CD8+ T cells from WT, Cre+, and Cre− mice, which were all equivalent, while proliferation of cells from conventional IL-2(−/−) mice was compromised. Splenocytes from IL-2 deficient conventional IL-2(−/−) mice produced low or undetectable other γc-chain cytokines (IL-4, IL-7, IL-9, IL-13, IL-15, and IL-21), whereas production of these γc-chain cytokines from IL-2-deficient conditional IL-2(−/−) Cre+ mice were comparable with WT and Cre− mice. These results indicate that CD4+ and CD8+ T cell blastogenesis cannot be attributable to IL-2 alone, but a switch to aerobic glycolysis was attributable to IL-2, and proliferation after CD3/CD28 activation is dependent on γc-chain cytokines, and not CD3/28 triggering per se
Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
List of Ethics Committees. (DOCX 38 kb
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis
Background This study evaluated two doses of etoricoxib (60 and 90 mg) vs.
naproxen 1000 mg in subjects with ankylosing spondylitis (AS). Methods This
was a 2-part, double-blind, active comparator-controlled non-inferiority study
in subjects ≥18 years of age with AS. In Part I, subjects were randomized to
naproxen 1000 mg; etoricoxib 60 mg, and 90 mg. In Part II, naproxen and
etoricoxib 90 mg subjects continued on the same treatment; subjects on
etoricoxib 60 mg either continued on 60 mg or escalated to 90 mg. Part I (6
weeks) assessed the efficacy of A) etoricoxib 60 mg vs. naproxen and B) 90 mg
vs. naproxen according to the time-weighted average change from baseline in
Spinal Pain Intensity (SPI; 0–100 mm VAS) (primary endpoint). The non-
inferiority margin was set at 8 mm for SPI. In Part II (20 weeks) we evaluated
the potential benefit of increasing from 60 to 90 mg (predefined minimum
clinically important difference = 6 mm in SPI) for inadequate responders (<50
% improvement from baseline in SPI) onetoricoxib 60 mg in Part I. Results In
total, 1015 subjects were randomized to receive etoricoxib 60 mg (N = 702),
etoricoxib 90 mg (N = 156), and naproxen 1000 mg (N = 157); 70.9 % were male
and the mean age was 45.2 years. There were 919 subjects who completed Part I
and all continued to Part II. In Part I, SPI change was non-inferior for both
etoricoxib doses vs. naproxen. In both Part I and II, the incidence of adverse
events (AEs), drug-related AEs, and serious adverse events (SAEs) were similar
between the 3 treatment groups. Conclusion Both doses of etoricoxib were non-
inferior to naproxen. All treatments were well tolerated. Etoricoxib 60 and 90
mg effectively control pain in patients with AS, with 60 mg once daily as the
lowest effective dose for most patients. Trial registration Clinical Trials
Registry # NCT01208207. Registered on 22 September 2010
Adequate immune response ensured by binary IL-2 and graded CD25 expression in a murine transfer model
The IL-2/IL-2Ralpha (CD25) axis is of central importance for the interplay of
effector and regulatory T cells. Nevertheless, the question how different
antigen loads are translated into appropriate IL-2 production to ensure
adequate responses against pathogens remains largely unexplored. Here we find
that at single cell level, IL-2 is binary (digital) and CD25 is graded
expressed whereas at population level both parameters show graded expression
correlating with the antigen amount. Combining in vivo data with a
mathematical model we demonstrate that only this binary IL-2 expression
ensures a wide linear antigen response range for Teff and Treg cells under
real spatiotemporal conditions. Furthermore, at low antigen concentrations
binary IL-2 expression safeguards by its spatial distribution selective STAT5
activation only of closely adjacent Treg cells regardless of their antigen
specificity. These data show that the mode of IL-2 secretion is critical to
tailor the adaptive immune response to the antigen amount
Immunotherapy with Canarypox Vaccine and Interleukin-2 for HIV-1 Infection: Termination of a Randomized Trial
OBJECTIVES: To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation. DESIGN: This was a Phase II randomized, partially double blinded, 2×2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk. SETTING: The Weill-Cornell General Clinical Research Center. PARTICIPANTS: Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4(+) T cells/μl. INTERVENTIONS: An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every 4 wk for four doses, and low-dose IL-2 administered daily for 12–24 wk. OUTCOME MEASURES: Primary endpoints: (1) Proportion of participants with undetectable plasma HIV RNA during trial Step II, (2) mean log(10) HIV RNA copies/ml ([HIV]) from weeks 21–25, and (3) proportion of individuals eligible for trial Step III. RESULTS: 44 participants were randomized, but 16 withdrew or were withdrawn before completing Step II. As all participants underwent viral relapse in Step II, the study was terminated after 28 participants completed Step II. Among the four groups, there was no difference in mean [HIV] or the proportion of individuals with < log(10) 4.48 HIV; no difference between the mean [HIV] of the two groups that received ALVAC (n = 17) versus placebo (n = 11); and no significant difference between the mean [HIV] of the two groups that received IL-2 (n = 11) versus placebo (n = 17). CONCLUSIONS: Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy
Negative Feedback Regulation of T Cells via Interleukin-2 and FOXP3 Reciprocity
As interleukin-2 (IL2) is central to the clonal expansion of antigen-selected T cells, we investigated the relationship between IL2 and the negative regulatory transcription factor FOXP3. We found IL2 to be responsible for T cell antigen receptor (TCR)-activated FOXP3 expression by both CD4+ and CD8+ human T cells, and as anticipated, FOXP3 expression restricted TCR-stimulated IL2 expression. However, no evidence could be found that FOXP3+ cells actively suppress IL2 expression by FOXP3- cells. These data are consistent with an IL2/FOXP3-dependent negative feedback loop that normally regulates the T cell immune response. It follows that a defect in this negative feedback loop as a result of a deficiency of either IL2 or FOXP3 will lead to a hyperproliferative autoimmune syndrome, without the necessity of invoking an active suppressive function for FOXP3+ T cells